तुलना करने के लिए मीट्रिक्स | HEMO | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधHEMOपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −3.8x | −5.4x | −0.2x | |
PEG अनुपात | −0.28 | −0.05 | 0.00 | |
क़ीमत/बुक | 9.9x | 6.6x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 11.3x | 2.8x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 277.6% | 60.5% | |
उचित मूल्य अपसाइड | अनलॉक करें | −4.4% | 7.8% | अनलॉक करें |
Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of treatments for blood cancer. The company’s lead product candidate is the HG-CT-1 therapy for the treatment of relapsed or refractory acute myeloid leukemia. It also develops chimeric bait receptor to treat viral infections derived and for certain cancer and neurological conditions; and CDX bi-specific antibody which eliminates hematopoietic stem cells/hematopoietic progenitors in a patient using bi-specific antibodies; and therapies for the improvement of bone marrow and blood stem cell transplant procedures. Hemogenyx Pharmaceuticals Plc was incorporated in 2013 and is headquartered in London, the United Kingdom.